FTC order could ease biopharma competition
European Pharmaceutical Review
SEPTEMBER 4, 2023
to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.
Let's personalize your content